Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AlphaRx, Inc.
AlphaRx, Proprius Pharmaceuticals sign license deal for Indaflex
May 8th, 2006
AlphaRx, Inc., (ALRX) and Proprius Pharmaceuticals, Inc., have entered into a license agreement giving Proprius exclusive global rights (with the exception of Asia and Mexico) to AlphaRx's topical NSAID, Indaflex 2.5% Indomethacin Cream. Indaflex, which makes use of AlphaRx's proprietary formulation technology to deliver indomethacin through the skin and directly to the soft tissue surrounding the joint, is currently in phase II clinical development in Canada for the treatment of osteoarthritis. In addition to Indaflex, the agreement gives Proprius rights to successor products and to all other topical NSAID products developed by AlphaRx. ...
Source: Biotech Week (2006-05-08)
|
